Centrose discovered that in diseased cells, CD38 forms a tight association with the NKA. CD38 is involved in many aspects of cell growth and inflammation and represents a new therapeutic target for cancer and inflammatory diseases. CD38 expression is also involved inflammation-associated steroid resistance.
EDC8 combines an anti-CD38 antibody with a powerful steroid and acts on cells that express CD38 complexes. In addition, Centrose has shown that certain cancer cells that initially do not express these complexes, can also be induced to so by the administration of ATRA, a safe and approved vitamin A derivative.
There are currently no CD38 specific antibody drug conjugates in development.